Susquehanna Fundamental Investments, LLC Editas Medicine, Inc. Transaction History

Susquehanna Fundamental Investments, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$6.25 - $11.11 $336,400 - $597,984	-53,824 Reduced 45.12%	65,463 $663 Million
Q2 2023 Aug 11, 2023	SELL	$6.36 - $11.47 $484,727 - $874,186	-76,215 Reduced 38.98%	119,287 $981,000
Q4 2022 Feb 14, 2023	BUY	$8.32 - $13.21 $1.63 Million - $2.58 Million	195,502 New	195,502 $1.73 Million
Q2 2021 Aug 11, 2021	SELL	$31.29 - $56.64 $364,278 - $659,402	-11,642 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$39.71 - $90.58 $462,303 - $1.05 Million	11,642 New	11,642 $489,000
Q4 2020 Feb 16, 2021	SELL	$27.07 - $84.35 $774,202 - $2.41 Million	-28,600 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$18.5 - $34.34 $529,100 - $982,124	28,600 New	28,600 $846,000

250

57.1M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $83.9M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.